The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.

J Neural Transm (Vienna) 2016 Apr 25;123(4):439-45. Epub 2016 Jan 25.

German Centre for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, 81377, Munich, Germany.

Formation of toxic α-synuclein oligomers appears to be a key underlying pathological mechanism of synucleinopathies such as Parkinson's disease or multiple system atrophy (MSA). Given that Epigallocatechin-gallate has been shown to inhibit α-synuclein aggregation, it might represent a causal treatment option. Therefore, we set out to evaluate the safety, tolerability and a potential disease-modifying effect of Epigallocatechin-gallate in patients with MSA after 48 weeks of treatment. Power calculation was performed on existing natural history data on the progression of the Unified MSA Rating Scale as primary readout parameter. To assess the efficacy of Epigallocatechin-gallate versus placebo regarding the reduction of disease progression measured during the study period (80 % power, 5 % p level, 50 % effect size) 36 patients per group are needed. Considering a drop-out rate of 20 % a total of 86 patients will be recruited in this multicentre study. These data provide a solid rationale to investigate whether supplementation of Epigallocatechin-gallate can delay the progression of the MSA-related disability.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-016-1507-8DOI Listing
April 2016
36 Reads

Publication Analysis

Top Keywords

system atrophy
8
multiple system
8
treatment power
4
power calculation
4
weeks treatment
4
msa weeks
4
patients will
4
natural history
4
total patients
4
performed existing
4
existing natural
4
rate total
4
calculation performed
4
patients msa
4
drop-out rate
4
disease-modifying epigallocatechin-gallate
4
set evaluate
4
period power
4
multicentre study
4
option set
4

References

(Supplied by CrossRef)

J Bieschke et al.
Proc Natl Acad Sci USA 2010

M Caruana et al.
FEBS Lett 2011

H Checkoway et al.
Am J Epidemiol 2002

B Dehay et al.
Lancet Neurol 2015

R Dodel et al.
Mov Disord 2010

A Fanciulli et al.
N Engl J Med 2015

PO Fernagut et al.
Neurobiol Dis 2014

S Gilman et al.
Neurology 2008

G Hu et al.
Mov Disord 2007

HJ Huppertz et al.
Neuroimage 2010

CL Kragh et al.
J Biol Chem 2009

Similar Publications